a public good project by the
Synthesis
Company
of California

© 2026

Alan T. Henley | doi.page

0 works0 citations0 h-index

Alan T. Henley

Institute of Cancer Research(GB)Cancer Research UK(GB)

Publications by Year

Research Areas

PI3K/AKT/mTOR signaling in cancer, Biochemical and Molecular Research, Metabolomics and Mass Spectrometry Studies, Protein Kinase Regulation and GTPase Signaling, Microtubule and mitosis dynamics

Most-Cited Works

→ Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases(2007)349 cited
→ Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941(2009)271 cited
→ ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma(2019)118 cited
→ Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930(2010)86 cited
→ Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt)(2010)83 cited
→ Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen(2015)79 cited

→ Structure-Based Design of Orally Bioavailable 1H-Pyrrolo[3,2-c]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1)(2013)79 cited

→ Aurora Isoform Selectivity: Design and Synthesis of Imidazo[4,5-b]pyridine Derivatives as Highly Selective Inhibitors of Aurora-A Kinase in Cells(2013)77 cited

→ Achieving In Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders(2020)73 cited

→ Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia(2012)69 cited